ACADIA PHARMACEUTICALS INC — Director's Dealing 2016

Mar 4, 2016

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: ACADIA PHARMACEUTICALS INC (ACAD)
CIK: 0001070494
Period of Report: 2016-03-02

Reporting Person: Baity Glenn (N/A)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2016-03-02	Common Stock	M	7000	$15.37	Acquired	69921	Direct
2016-03-02	Common Stock	S	7000	$20.7971	Disposed	62921	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2016-03-02	Stock Option (right to buy)	$15.37	M	7000	Disposed	2016-03-13	Common Stock (7000)	Direct

Footnotes

F1: Includes 22 and 476 shares acquired on May 15, 2015 and November 13, 2015, respectively, by Mr. Baity under the ACADIA Pharmaceuticals Employee Stock Purchase Plan.

F2: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person in September 2015.

F3: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $20.76 to $20.84 per share, inclusive.The reporting person undertakes to provide ACADIA Pharmaceuticals Inc., any security holder of ACADIA Pharmaceuticals Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the foregoing range.

F4: 25% of the shares subject to the Stock Option vested and became exercisable on March 14, 2007. The remaining shares vested and became exercisable thereafter in 36 equal monthly installments.